Translate Bio

Developing a new class of potentially transformative mRNA medicines

Translate Bio is a clinical stage biotechnology company developing a new class of potentially transformative mRNA based medicines to treat diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform (MRT), Translate is seeking to address a wide range of diseases that are not well managed with existing protein or gene replacement therapies. The company’s lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.

Status
NASDAQ: TBIO
Year of Investment
2019
Strategy
Life Sciences
Location
Lexington, Massachusetts